We are live on !
Find out more
Dmitry Balyasny Balyasny Asset Management
AUM
$80.2B
Turnover
42.78%
1-Year Est. Return
51.53%
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+51.53%
3 Year Est. Return
+149.76%
5 Year Est. Return
+199.38%
10 Year Est. Return
+875.18%
AUM
$80.2B
AUM Growth
+$3.12B
(+4%)
Cap. Flow
-$3.01B
Cap. Flow % of AUM
Cap. Flow %
-3.76%
Top 10 Holdings %
Top 10 Hldgs %
13.57%
Holding
3,665
New
834
Increased
989
Reduced
995
Closed
734
Avg Time Held
Equity + Options
1.1
years
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.8
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 36.95% |
| 2 | Technology | 12.69% |
| 3 | Industrials | 10% |
| 4 | Consumer Discretionary | 7.97% |
| 5 | Healthcare | 7.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
501
Bunge Global
BG
$19.4B
| $31.5M | 0.04% |
294,950
-101,274
| -26% | -$12.4M |
2025 Q2
4 quarters
|
|
502
Core Natural Resources Inc
CNR
$4.01B
| $31.5M | 0.04% |
393,337
-17,481
| -4% | -$1.55M |
2024 Q1
9 quarters
|
|
503
CALL
Fox Class A
FOXA
$28.6B
| $31.3M | 0.04% |
+600,000
| New | +$37.1M |
2026 Q2
0 quarters
|
|
504
Rayonier
RYN
$6.46B
| $31.2M | 0.04% |
1,467,064
-697,826
| -32% | -$14.6M |
2026 Q1
1 quarter
|
|
505
Novanta
NOVT
$5.52B
| $31.1M | 0.04% |
191,700
+157,453
| +460% | +$22.8M |
2024 Q4
6 quarters
|
|
506
PUT
Airbnb
ABNB
$112B
| $31M | 0.04% |
216,600
-66,500
| -23% | -$9.07M |
2022 Q1
17 quarters
|
|
507
PUT
Lam Research
LRCX
$277B
| $31M | 0.04% |
71,500
-27,300
| -28% | -$8.29M |
2024 Q4
6 quarters
|
|
508
eBay
EBAY
$53.1B
| $30.9M | 0.04% |
276,816
-349,466
| -56% | -$37.3M |
2025 Q1
5 quarters
|
|
509
CALL
Costco
COST
$472B
| $30.9M | 0.04% |
33,000
+24,800
| +302% | +$24.7M |
2023 Q1
13 quarters
|
|
510
Madison Air Solutions
MAIR
$12.3B
| $30.8M | 0.04% |
+790,973
| New | +$30.8M |
2026 Q2
0 quarters
|
|
511
Lantheus
LNTH
$6.61B
| $30.8M | 0.04% |
277,821
-261,561
| -48% | -$24.4M |
2022 Q4
14 quarters
|
|
512
Enliven Therapeutics
ELVN
$3.79B
| $30.8M | 0.04% |
607,189
+297,164
| +96% | +$12.6M |
2026 Q1
1 quarter
|
|
513
CALL
Visa
V
$788B
| $30.8M | 0.04% |
89,800
+68,600
| +324% | +$22M |
2023 Q2
12 quarters
|
|
514
Kinder Morgan
KMI
$68.1B
| $30.6M | 0.04% |
957,378
-986,912
| -51% | -$31.8M |
2023 Q3
11 quarters
|
|
|
EROC
515
ERock Inc
EROC
$397M
| $30.4M | 0.04% |
+2,099,619
| New | +$33.4M |
2026 Q2
0 quarters
|
|
516
Tapestry
TPR
$26.7B
| $30.4M | 0.04% |
207,777
-78,174
| -27% | -$11.2M |
2025 Q4
2 quarters
|
|
517
CALL
ASML
ASML
$583B
| $30.2M | 0.04% |
15,200
+5,300
| +54% | +$8.44M |
2023 Q3
11 quarters
|
|
518
PUT
Vertiv
VRT
$77.2B
| $30.2M | 0.04% |
90,100
+34,000
| +61% | +$10.8M |
2024 Q3
7 quarters
|
|
519
Cleveland-Cliffs
CLF
$7B
| $30.1M | 0.04% |
3,208,119
+474,720
| +17% | +$5.22M |
2025 Q1
5 quarters
|
|
520
Atlantic Union Bankshares
AUB
$5.62B
| $30.1M | 0.04% |
711,227
-219,499
| -24% | -$8.38M |
2025 Q2
4 quarters
|
|
521
State Street
STT
$46.5B
| $30.1M | 0.04% |
177,284
+173,119
| +4,157% | +$26.7M |
2024 Q2
8 quarters
|
|
522
Encompass Health
EHC
$13.9B
| $30M | 0.04% |
296,939
+243,080
| +451% | +$25.2M |
2025 Q4
2 quarters
|
|
523
iShares Russell 2000 ETF
IWM
$78.5B
| $29.9M | 0.04% |
+99,639
| New | +$28M |
2026 Q2
0 quarters
|
|
524
Crescent Biopharma
CBIO
$507M
| $29.9M | 0.04% |
1,662,917
+152,884
| +10% | +$2.98M |
2025 Q4
2 quarters
|
|
525
Air Products & Chemicals
APD
$69.3B
| $29.9M | 0.04% |
102,043
-623,041
| -86% | -$181M |
2023 Q1
13 quarters
|
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $3.01B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 37% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.